These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11958994)

  • 1. Benzimidazoles and isosteric compounds as potent and selective factor Xa inhibitors.
    He W; Hanney B; Myers MR; Condon S; Becker MR; Spada AP; Burns C; Brown K; Colussi D; Chu V
    Bioorg Med Chem Lett; 2002 Mar; 12(6):919-22. PubMed ID: 11958994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors.
    Beaulieu F; Ouellet C; Ruediger EH; Belema M; Qiu Y; Yang X; Banville J; Burke JR; Gregor KR; MacMaster JF; Martel A; McIntyre KW; Pattoli MA; Zusi FC; Vyas D
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1233-7. PubMed ID: 17197177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
    Chen TC; Yu DS; Huang KF; Fu YC; Lee CC; Chen CL; Huang FC; Hsieh HH; Lin JJ; Huang HS
    Eur J Med Chem; 2013 Nov; 69():278-93. PubMed ID: 24051300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.
    Frazier K; Jazan E; McBride CM; Pecchi S; Renhowe PA; Shafer CM; Taylor C; Bussiere D; He MM; Jansen JM; Lapointe G; Ma S; Vora J; Wiesmann M
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2247-51. PubMed ID: 16446087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.
    Zhao Z; Arnaiz DO; Griedel B; Sakata S; Dallas JL; Whitlow M; Trinh L; Post J; Liang A; Morrissey MM; Shaw KJ
    Bioorg Med Chem Lett; 2000 May; 10(9):963-6. PubMed ID: 10853669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.
    Maiwald A; Hammami M; Wagner S; Heine A; Klebe G; Steinmetzer T
    J Enzyme Inhib Med Chem; 2016; 31(sup1):89-97. PubMed ID: 27168215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
    Skalitzky DJ; Marakovits JT; Maegley KA; Ekker A; Yu XH; Hostomsky Z; Webber SE; Eastman BW; Almassy R; Li J; Curtin NJ; Newell DR; Calvert AH; Griffin RJ; Golding BT
    J Med Chem; 2003 Jan; 46(2):210-3. PubMed ID: 12519059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of (benzimidazol-2-yl)aniline derivatives as glycogen phosphorylase inhibitors.
    Galal SA; Khattab M; Andreadaki F; Chrysina ED; Praly JP; Ragab FAF; El Diwani HI
    Bioorg Med Chem; 2016 Nov; 24(21):5423-5430. PubMed ID: 27624527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and characterization of a potent and selective protein tyrosine phosphatase inhibitor, 2.
    Hamaguchi T; Takahashi A; Kagamizono T; Manaka A; Sato M; Osada H
    Bioorg Med Chem Lett; 2000 Dec; 10(23):2657-60. PubMed ID: 11128645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.
    Bilodeau MT; Cunningham AM; Koester TJ; Ciecko PA; Coll KE; Huckle WR; Hungate RW; Kendall RL; McFall RC; Mao X; Rutledge RZ; Thomas KA
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2485-8. PubMed ID: 12852948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.
    Bauer SM; Goldman EA; Huang W; Su T; Wang L; Woolfrey J; Wu Y; Zuckett JF; Arfsten A; Huang B; Kothule J; Lin J; May B; Sinha U; Wong PW; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4045-50. PubMed ID: 15225723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
    Ueno H; Katoh S; Yokota K; Hoshi J; Hayashi M; Uchida I; Aisaka K; Hase Y; Cho H
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4281-6. PubMed ID: 15261287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
    Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
    J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispyridinium cyclophanes: novel templates for human choline kinase inhibitors.
    Conejo-García A; Campos JM; Sánchez-Martín RM; Gallo MA; Espinosa A
    J Med Chem; 2003 Aug; 46(17):3754-7. PubMed ID: 12904080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N(2)-Aroylanthranilamide inhibitors of human factor Xa.
    Yee YK; Tebbe AL; Linebarger JH; Beight DW; Craft TJ; Gifford-Moore D; Goodson T; Herron DK; Klimkowski VJ; Kyle JA; Sawyer JS; Smith GF; Tinsley JM; Towner RD; Weir L; Wiley MR
    J Med Chem; 2000 Mar; 43(5):873-82. PubMed ID: 10715154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzimidazole derivatives as potent inhibitors of milk xanthine oxidase.
    Rudnicka R; Bojarska E; Kazimierczuk Z
    Acta Pol Pharm; 2004 Dec; 61 Suppl():37-9. PubMed ID: 15909934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
    Han Q; Dominguez C; Stouten PF; Park JM; Duffy DE; Galemmo RA; Rossi KA; Alexander RS; Smallwood AM; Wong PC; Wright MM; Luettgen JM; Knabb RM; Wexler RR
    J Med Chem; 2000 Nov; 43(23):4398-415. PubMed ID: 11087565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.
    Lahue BR; Ma Y; Shipps GW; Seghezzi W; Herbst R
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3405-9. PubMed ID: 19481450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.